Press release
Aplastic Anemia Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight
Unlock key insights into the Aplastic Anemia Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Aplastic Anemia Therapeutics Market Outlook [https://www.delveinsight.com/sample-request/aplastic-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Aplastic Anemia Market Report
* In April 2025, Fred Hutchinson Cancer Center announced a phase II trial tests how well a ruxolitinib-based graft versus host disease (GVHD) prevention (prophylaxis) regimen works before, during, and after bone marrow/stem cell transplantation (hematopoietic cell transplantation [HCT]) in patients with acquired aplastic anemia.
* In March 2025, Novartis Pharmaceuticals announced a phase II study to characterize the pharmacokinetics (PK) after oral administration of eltrombopag in combination with immunosuppressive therapy in pediatric patients with previously untreated or relapsed/refractory severe aplastic anemia or recurrent aplastic anemia.
* The total Aplastic Anemia Treatment Market Size was found to be ~USD 270 million in 2023 in the 7MM, which is further expected to increase by 2034.
* Among the 7MM, Japan accounts for the second highest total aplastic anemia drugs market. The Aplastic Anemia Treatment Market Size in Japan has been assessed to be ~USD 35 million in 2023, expected to increase during the forcast period.
* During the forecast period, Aplastic Anemia pipeline candidates such as Omidubicel-onlv, REGN7257, and ALVAIZ (eltrombopag choline) are expected to drive the rise in Aplastic anemia market size.
* Among EU4 and the UK, Germany accounts for the highest Aplastic Anemia Treatment Market Size with ~USD 14 million in 2023, followed by France.
* Aplastic Anemia Treatment Market Size is expected to increase due to several factors such as an increase in disease incidence in Asian countries, high patient uptake of PROMACTA (until expected patent expiry in 2025), approval of Teva Pharma's ALVAIZ in the US, and Kyowa Kirin's ROMIPLATE in Japan along with the expected launch of potential emerging therapies.
* The leading Aplastic Anemia Companies such as Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals, and others.
* Promising Aplastic Anemia Pipeline Therapies such as Romiplostim, Eltrombopag, PF-06462700, AMG531, Rabbit ATG, Cyclosporine and others.
Stay ahead in the competitive landscape of the Aplastic Anemia Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Aplastic Anemia Treatment Market Size [https://www.delveinsight.com/sample-request/aplastic-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Aplastic Anemia Epidemiology Segmentation in the 7MM
* Aplastic Anemia Incident Cases
* Aplastic Anemia Severity-Specific Cases
* Aplastic Anemia Age-specific Cases
Download the report to understand which factors are driving Aplastic Anemia epidemiology trends @ Aplastic Anemia Prevalence [https://www.delveinsight.com/sample-request/aplastic-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Aplastic Anemia Marketed Therapies
* ALVAIZ (eltrombopag choline): Teva Pharmaceuticals
ALVAIZ (eltrombopag choline) is an oral thrombopoietin (TPO) receptor agonist that works to increase platelet production by interacting with the transmembrane domain of the human TPO-receptor to initiate signaling cascades that induce proliferation and differentiation of megakaryocytes. Lowest dose of ALVAIZ is use to achieve and maintain a hematologic response. Dose adjustments are based upon the platelet count. Hematologic response requires dose titration, generally up to 108 mg, and may take up to 16 weeks after starting ALVAIZ.
* ROMIPLATE (romiplostim; AMG531): Kyowa Kirin/Amgen
ROMIPLATE is composed of recombinant protein acting on the thrombopoietin receptor, which has been licensed from Amgen (K-A) to Kyowa Kirin. It was launched as a drug for idiopathic thrombocytopenic purpura (ITP) in April 2011 and for aplastic anemia in patients who had an inadequate response to conventional therapy in June 2019 in Japan. The drug is composed of recombinant protein stimulating hematopoiesis via acting on the thrombopoietin receptors; Acts directly on megakaryocytic progenitor cells and exerts platelet hematopoietic effects. In addition, this drug promotes the proliferation and differentiation of megakaryocytic progenitor cells by binding to and activating thrombopoietin receptors.
Aplastic Anemia Emerging Therapies
* REGN7257: Regeneron Pharmaceuticals
It's a gc cytokine receptor antibody that targets the common g chain (gc; IL-2RG) found in interleukin (IL) receptors for various gc cytokines, including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. It was developed to investigate the potential of targeting gc cytokines for the prevention and treatment of T-cell-mediated diseases. By blocking the signaling of GC cytokines, REGN7257 aims to ameliorate T-cell-mediated pathogenesis. This antibody offers a promising approach to understand better the role of gc cytokines in inflammatory and autoimmune disease settings, where the lack of appropriate neutralizing antibodies recognizing IL-2RG has been a challenge.
* OMISIRGE (omidubicel): Gamida Cell
OMISIRGE is a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from cord blood. It is indicated for use in adults and pediatric patients aged 12 years and older with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning. The therapy aims to reduce the time to neutrophil recovery and the incidence of infection in this patient population. Omisirge has received approval for use in hematological malignancies and is currently undergoing evaluation in an ongoing investigator-sponsored Phase I/II study focusing on patients with severe aplastic anemia.
To learn more about Aplastic Anemia Treatment guidelines, visit @ Aplastic Anemia Market Drivers and Barriers [https://www.delveinsight.com/sample-request/aplastic-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Aplastic Anemia Market Outlook
The Aplastic Anemia Prognosis, varies based on the severity of the condition. Some cases can be successfully treated, while others may progress to severe complications, such as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Historically, the primary modalities for treating aplastic anemia have been IST and BMT in eligible patients. For individuals with SAA/VSAA deemed suitable for transplant-based interventions, age emerges as a pivotal determinant influencing survival post-matched sibling donor (MSD) allogeneic transplantation. Notably, older patients, often having undergone prior IST, presenting with additional comorbidities, diminished performance status, and an extended duration between diagnosis and BMT, exhibit distinctive challenges in outcomes, with fludarabine-containing regimens offering more promising results in this demographic, albeit based on limited retrospective analyses.
Aplastic Anemia Treatment Market
Aplastic anemia is a rare and severe nonmalignant disease characterized by autoimmune destruction of early hematopoietic cells. Aplastic anemia can be categorized into congenital and acquired forms. Inherited forms are rare and include Fanconi Anemia, Congenital Keratosis, Congenital Pure Red Cell Aplasia, and Shwachman-Diamond Syndrome. Most cases of acquired aplastic anemia occur unrelated to any identifiable causes or for unknown reasons. Researchers believe that most are due to the immune system mistakenly targeting the bone marrow. Specific symptoms vary from case to case. Some individuals may have mild symptoms that remain stable for many years; others may have serious symptoms that can progress to life-threatening complications.
Explore the dynamics of the Aplastic Anemia Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Aplastic Anemia Ongoing Clinical Trials Analysis [https://www.delveinsight.com/sample-request/aplastic-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Aplastic Anemia Market Report
* Coverage- 7MM
* Study Period- 2020-2034
* Aplastic Anemia Companies- Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals , and others.
* Aplastic Anemia Pipeline Therapies- Romiplostim, Eltrombopag, PF-06462700, AMG531, Rabbit ATG, Cyclosporine, and others.
* Aplastic Anemia Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
* Aplastic Anemia Unmet Needs, KOL's views, Analyst's views, Aplastic Anemia Market Access and Reimbursement
Table of Contents
1. Key Insights
2. Aplastic Anemia Market Report Introduction
3. Executive Summary of Aplastic Anemia
4. Aplastic Anemia Market Overview at a Glance
5 Key Events
6 Aplastic Anemia Epidemiology and Market Forecast Methodology
7 Aplastic Anemia Disease Background and Overview
8 Aplastic Anemia Treatment and Management of Aplastic Anemia
9 Aplastic Anemia Epidemiology and Patient Population
10 Aplastic Anemia Patient Journey
11 Aplastic Anemia Marketed Therapies
12 Aplastic Anemia Emerging Drugs
13 Aplastic Anemia: Market Analysis
14 Aplastic Anemia Unmet Needs
15 Aplastic Anemia SWOT Analysis
16 Aplastic Anemia KOL Views
17 Aplastic Anemia Market Access and Reimbursement
18 Appendix
19 DelveInsight Capabilities
20 Disclaimer
21 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=aplastic-anemia-treatment-market-size-in-7mm-is-expected-to-grow-at-a-decent-cagr-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/aplastic-anemia-market
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Aplastic Anemia Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight here
News-ID: 3993465 • Views: …
More Releases from ABNewswire
TALLSEN Strengthens Global Presence Through Brand Partnership with TouchWood in …
The collaboration marks a new milestone in international expansion, uniting German craftsmanship with Saudi innovation.
TALLSEN, an international hardware brand renowned for its German-origin craftsmanship and European-standard manufacturing, has officially entered a brand partnership with TouchWood , a fast-growing Saudi Arabian brand founded by Mr. Abdalla in Jeddah. This collaboration represents a significant step in TALLSEN's ongoing global expansion and its commitment to excellence, innovation, and local partnership development.
Image: https://www.abnewswire.com/upload/2025/10/2e3d1a1caf0cb8c422d60d2df66f29e6.jpg
A Meeting…
YummyPic Launches AI Food Photography Platform That Turns Basic Dish Photos into …
Image: https://www.abnewswire.com/upload/2025/10/e806fbc34047688867fdaa7be2873709.jpg
YummyPic [https://yummypic.com/], an innovative AI-powered photography platform, has officially launched to help restaurants transform ordinary food photos into professional, mouthwatering menu images, all in under 60 seconds. Designed for busy restaurateurs, YummyPic eliminates the need for expensive photoshoots, offering a fast, affordable, and visually stunning solution for platforms like DoorDash, Uber Eats, and Grubhub.
Revolutionizing Food Photography for the Digital Era
In a competitive food delivery landscape, poor menu photos can…
"Digital Marketing $1": Momentum Iplus Brings a $20,000-Value Opportunity to Sma …
Momentum Iplus has launched the Digital Marketing $1 campaign, a community-focused initiative that gives qualified small businesses access to a marketing support package valued at up to $20,000 for only $1. From Google Business Profile optimization to professional websites and international press visibility, the program helps underserved entrepreneurs strengthen their visibility, credibility, and growth potential.
Image: https://static.wixstatic.com/media/12d9b1_bfd6e48ccdb94ebfa0995e0c7c8bdb6f~mv2.png/v1/fill/w_1480,h_828,al_c,q_90,usm_0.66_1.00_0.01,enc_avif,quality_auto/12d9b1_bfd6e48ccdb94ebfa0995e0c7c8bdb6f~mv2.png
The Challenge: Digital Gaps Costing Small Businesses Customers
Research suggests that nearly 70% of Vietnamese-owned small…
"Digital Marketing $1" by Momentum Iplus: A Community-Driven Campaign for Small …
For many small and medium-sized businesses in the U.S., particularly within the Vietnamese community, digital visibility remains a critical challenge. Recent estimates suggest that nearly 70% of Vietnamese-owned SMEs, especially nail salons and restaurants, do not fully meet the basic standards of Google Business Profiles. This lack of optimization can result in lost opportunities, with businesses potentially missing 30-40% of customers who search for local services online.
Image: https://static.wixstatic.com/media/12d9b1_7a6e4c46c3c14a1bb71e96f086e80f83~mv2.png/v1/fill/w_1480,h_986,al_c,q_90,usm_0.66_1.00_0.01,enc_avif,quality_auto/12d9b1_7a6e4c46c3c14a1bb71e96f086e80f83~mv2.png
A Community-Focused Campaign…
More Releases for Aplastic
Acquired Aplastic Anemia Market: Growth Trends to Watch
Acquired Aplastic Anemia Market valued at USD X.X Billion in 2024 and is projected to reach USD X.X Billion by 2032, growing at a CAGR of X.X% from 2025 to 2032.
What is the Acquired Aplastic Anemia Market and Why is It Significant?
The Acquired Aplastic Anemia market refers to the segment of healthcare focused on diagnosing, treating, and managing acquired aplastic anemia, a rare blood disorder where the bone marrow fails…
Strategic Partnerships Drive Advancements In Aplastic Anemia Treatment And Resea …
How Are the key drivers contributing to the expansion of the aplastic anemia market?
The escalating expenses on healthcare are anticipated to stimulate the aplastic anemia market's expansion in the future. This growth in healthcare spending is mainly attributed to factors like aging populations and rising chronic illnesses that necessitate expensive treatments. Investments in healthcare facilitate treatments for aplastic anemia by providing funds for specialized medical institutions, innovative therapies, and research…
Leading Element Driving Change in the Aplastic Anemia Market in 2025: Impact Of …
What Is the Estimated Market Size and Growth Rate for the Aplastic Anemia Market?
The market size of aplastic anemia has seen considerable growth in past years. There is expected growth from $6.63 billion in 2024 to $7.03 billion in 2025, with a compound annual growth rate (CAGR) of 6.2%. The historic growth of this market can be credited to several factors, including a rise in the incidence of blood disorders,…
Aplastic Anemia Market: A Growing Need for Treatment
The aplastic anemia market has witnessed significant growth in recent years, driven by advancements in medical technology, increasing awareness of the condition, and the desire for effective treatment options. This post will delve into the market, exploring its size, share, opportunities, challenges, demand, and trends.
Market Size and Share
The aplastic anemia market is a substantial segment of the global hematology and oncology industry. While precise figures can vary depending on data…
Aplastic Anemia Treatment Market - Shaping the Future of Aplastic Anemia Health: …
Newark, New Castle, USA: The "Aplastic Anemia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Aplastic Anemia Treatment Market: https://www.growthplusreports.com/report/aplastic-anemia-treatment-market/8435
This latest report researches the industry structure,…
Global Acquired Aplastic Anemia Market Insights, Forecast
Acquired aplastic anemia is a rare, serious blood disorder, due to failure of the bone marrow failure to produce blood cells. Bone marrow is the spongy substance found in the center of the bones of the body, in adults mainly the spine, pelvis, and large bones of the legs. The global Acquired Aplastic Anemia market is valued at xx million US$ in 2018 and will reach xx million US$ by…
